Magnilife Psoriasis Care Cream
NDC Package 43689-0036-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Magnilife Psoriasis Care (graphite, daphne mezereum bark,) cream is apply generously to affected areas up to 4 times a day. This formulation utilizes a cream delivery system. Marketed by The Magni Group, Inc., this product is identified by NDC 43689-0036.

Identification & Billing

NDC Package Code
43689-0036-2
Package Description
1 JAR in 1 BOTTLE, UNIT-DOSE / 56 g in 1 JAR
Product Code
43689-0036
11-Digit Billing Format
43689003602

Clinical Specifications

Proprietary Name
Magnilife Psoriasis Care
Non-Proprietary Name
Graphite, Daphne Mezereum Bark,
Substance Name
Graphite; Daphne Mezereum Bark
Dosage Form
Cream - An emulsion, semisolid3 dosage form, usually containing > 20% water and volatiles5 and/or < 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
Usage Information
Apply generously to affected areas up to 4 times a day

Regulatory & Marketing

Labeler Name
The Magni Group, Inc.
Product Type
Human Otc Drug
Marketing Category
UNAPPROVED HOMEOPATHIC - A category specifying that a product is marketed as unapproved homeopathic product.
Start Marketing Date
06-29-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 43689-0036-2 identifies a specific commercial package of 1 jar in 1 bottle, unit-dose / 56 g in 1 jar of Magnilife Psoriasis Care, a human over the counter drug labeled by The Magni Group, Inc.. This cream is formulated for topical use and contains graphite; daphne mezereum bark as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by The Magni Group, Inc. on June 29, 2026. The current certification is valid through December 31, 2027.

How is this The Magni Group, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 43689003602. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
43689-0036-2
11-Digit CMS (5-4-2)
43689-0036-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.